Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial

Authors :: Susan R. Hintz
Denise Hug
Brenda B. Poindexter
Howard W. Kilbride
William Oh
Deanne E. Wilson-Costello
Michael B. Yang
Janell Fuller
Rosemary D. Higgins
Shawn Hirsch
Stephanie L. Merhar
Ann Marie Scorsone
Carol A. Cole
David K. Wallace
Kristi L. Watterberg
Amy K. Hutchinson
Graham E. Quinn
Kristin M. Zaterka-Baxter
Myriam Peralta-Carcelen
Martin S. Cogen
William R. Lucas
Richard J. Olson
Faruk H. Orge
Roy J. Heyne
Tarah T. Colaizy
Betty R. Vohr
Isabell B. Purdy
Conra Backstrom Lacy
Sara B. DeMauro
Dale L. Phelps
Michael W. Gaynon
John P Donahue
Tracy L. Nolen
Helen A. Mintz-Hittner
Heidi M. Harmon
Gary J. Myers
Andrea F. Duncan
Timothy W. Winter
Abhik Das
C. Michael Cotten
Yu-Guang He
Nathalie L. Maitre
Ricki F. Goldstein
Girija Natarajan
Kathryn M. Haider
Irena Tsui
Ira Adams-Chapman
Don L. Bremer
Source :: J Perinatol
Publication Year :: 2021
Publisher :: Springer Science and Business Media LLC, 2021.
Abstract: OBJECTIVE: This study evaluates the 24 month follow up for the NICHD Neonatal Research Network (NRN) Inositol for Retinopathy Trial. STUDY DESIGN: Bayley Scales of Infants Development-III and a standardized neurosensory examination were performed in infants enrolled in the main trial. Moderate/severe NDI was defined as BSID-III Cognitive or Motor composite score

Tools